{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:59:58Z","timestamp":1779897598591,"version":"3.53.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI21C2516"],"award-info":[{"award-number":["HI21C2516"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Amnestic mild cognitive impairment (aMCI) is often considered a precursor to Alzheimer\u2019s disease (AD) and represents a key therapeutic target for early intervention of AD. However, no treatments have been approved for MCI at present. Our previous pilot study has shown that Kami Guibi-tang (KGT), a traditional herbal prescription widely used in Korean medicine for treating amnesia, might be beneficial for improving general cognitive function of aMCI patients. We will conduct a larger-scale clinical trial to validate the findings of our pilot study and further examine the efficacy and safety of KGT in aMCI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This trial is designed as a randomized, double-blind, placebo-controlled clinical trial. A total of 84 aMCI patients will be recruited and randomized into the treatment and control groups. Participants will be administered either KGT or placebo granules for 24\u2009weeks, with a follow-up period of 12\u2009weeks after the last treatment. Primary outcomes will include changes in cognitive performance assessed using a neuropsychological test battery, called the Seoul Neuropsychological Screening Battery, between the baseline, post-intervention visit, and follow-up visit (24th and 36th week, respectively). Secondary outcomes will involve the rate of progression to AD, changes in neuroimaging signals assessed using structural magnetic resonance imaging (MRI), resting-state functional MRI (rs-fMRI), and task-based fMRI, and changes in blood biomarkers measured by the ratio of plasma amyloid-\u03b2 42\/40 levels (A\u03b242\/A\u03b240) between the baseline and post-intervention visit (24th week). For safety assessments, blood chemistry tests and electrocardiograms (ECG) will also be performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study aims to provide confirmatory evidence of the effect of the Korean herbal medicine, KGT, on improving cognitive function in patients with aMCI. We will identify the possible mechanisms underlying the effects of KGT using neuroimaging signals and blood biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Korean Clinical Trial Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/cris.nih.go.kr\/cris\/search\/detailSearch.do\/16918;\">https:\/\/cris.nih.go.kr\/cris\/search\/detailSearch.do\/16918;<\/jats:ext-link> Registration number: KCT0007039; Date of registration: February 24, 2022).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-022-03805-9","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:27:59Z","timestamp":1669976879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Kami Guibi-tang in patients with mild cognitive impairment: study protocol for a phase III, randomized, double-blind, and placebo-controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Hee-Yeon","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Bin","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Min","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geon-Ho","family":"Jahng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungwon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Yeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Uk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Sang","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Kwan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Nam","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Mi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"issue":"3","key":"3805_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/joim.12190","volume":"275","author":"RC Petersen","year":"2014","unstructured":"Petersen RC, Caracciolo B, Brayne C, et al. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214\u201328.","journal-title":"J Intern Med"},{"key":"3805_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","volume":"119","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia\u2014meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252\u201365.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"3805_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/YCO.0b013e328344696b","volume":"24","author":"TF Hughes","year":"2011","unstructured":"Hughes TF, Snitz BE, Ganguli M. Should mild cognitive impairment be subtyped? Curr Opin Psychiatry. 2011;24(3):237\u201342.","journal-title":"Curr Opin Psychiatry"},{"key":"3805_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1212\/01.wnl.0000252358.03285.9d","volume":"23","author":"P Fischer","year":"2007","unstructured":"Fischer P, Jungwirth S, Zehetmayer S, et al. Conversion from subtypes of mild cognitive impairment. Neurology. 2007;23:288\u201391.","journal-title":"Neurology."},{"key":"3805_CR5","first-page":"2017","volume-title":"Alzheimer\u2019s disease facts and figures","author":"A. s. Association","year":"2017","unstructured":"A. s. Association. Alzheimer\u2019s disease facts and figures; 2017. p. 2017."},{"issue":"8","key":"3805_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/15622975.2019.1696473","volume":"21","author":"S Kasper","year":"2020","unstructured":"Kasper S, Bancher C, Eckert A, et al. Management of mild cognitive impairment (MCI): the need for national and international guidelines. World J Biol Psychiatry. 2020;21(8):579\u201394.","journal-title":"World J Biol Psychiatry"},{"key":"3805_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1254\/jjp.54.375","volume":"54","author":"K Nishizawa","year":"1990","unstructured":"Nishizawa K, Saito H, Nishiyama N. Effects of Kamikihi-to, a traditional Chinese medicine, on passive and conditioned avoidance performance impairment in senescence accelerated mouse (SAM). Jpn J Pharmacol. 1990;54:375\u201382.","journal-title":"Jpn J Pharmacol"},{"key":"3805_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/ptr.2034","volume":"21","author":"N Egashira","year":"2007","unstructured":"Egashira N, Manome N, Kurauchi K, et al. Kamikihi-to, a Kampo medicine, ameliorates impairment of spatial memory in rats. Phytother Res. 2007;21:126\u20139.","journal-title":"Phytother Res"},{"key":"3805_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3109\/00207454.2011.602809","volume":"121","author":"C Tohda","year":"2011","unstructured":"Tohda C, Nakada R, Urano T, et al. Kamikihi-to (KKT) rescues axonal and synaptic degeneration associated with memory impairment in a mouse model of Alzheimer\u2019s disease, 5XFAD. Int J Neurosci. 2011;121:641\u20138.","journal-title":"Int J Neurosci"},{"key":"3805_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1447-0594.2007.00407.x","volume":"7","author":"K Higashi","year":"2007","unstructured":"Higashi K, Rakugi H, Yu H, et al. Effect of kihito extract granules on cognitive function in patients with Alzheimer\u2019s-type dementia. Geriatr Gerontol Int. 2007;7:245\u201351.","journal-title":"Geriatr Gerontol Int"},{"key":"3805_CR11","doi-asserted-by":"crossref","unstructured":"Shin HY, Kim HR, Jahng GH, et al. Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial. BMC Complement Med Ther. 2021;21(1):251.","DOI":"10.1186\/s12906-021-03428-6"},{"key":"3805_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"3805_CR13","volume-title":"Seoul neuropsychological screening battery (SNSB)","author":"Y Kang","year":"2003","unstructured":"Kang Y, Na DL. Seoul neuropsychological screening battery (SNSB). Seoul: Human Brain Research & Consulting Co; 2003."},{"key":"3805_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3346\/jkms.2010.25.7.1071","volume":"25","author":"H-J Ahn","year":"2010","unstructured":"Ahn H-J, Chin J, Park A, et al. Seoul neuropsychological screening battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia Patiens. J Korean Med Sci. 2010;25:1071\u20136.","journal-title":"J Korean Med Sci"},{"issue":"8","key":"3805_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"issue":"7691","key":"3805_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature."},{"issue":"26801","key":"3805_CR17","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6(26801):26801.","journal-title":"Sci Rep"},{"key":"3805_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000478520","volume":"44","author":"J Kim","year":"2017","unstructured":"Kim J, Na HK, Byun J, et al. Tracking cognitive decline in amnestic mild cognitive impairment and early-stage Alzheimer dementia: Mini-mental state examination versus neuropsychological battery. Dement Geriatr Cogn Disord. 2017;44:1\u20132.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"3805_CR19","first-page":"196","volume":"1","author":"K Kantarci","year":"2004","unstructured":"Kantarci K, Jack C Jr. Quantitative magnetic resonance techniques as surrogate markers in Alzheimer\u2019s disease. NeuroRx J Am Soc Exp Neurotherap. 2004;1:196\u2013205.","journal-title":"NeuroRx J Am Soc Exp Neurotherap"},{"key":"3805_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.trci.2018.04.007","volume":"4","author":"E Bayram","year":"2018","unstructured":"Bayram E, Caldwell JZK, Banks SJ. Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer's disease. Alzheimers Dement (N Y). 2018;4:395\u2013413.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"3805_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13195-018-0347-1","volume":"10","author":"E Canu","year":"2018","unstructured":"Canu E, Sarasso E, Filippi M, et al. Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review. Alzheimers Res Ther. 2018;10(1):21.","journal-title":"Alzheimers Res Ther"},{"key":"3805_CR22","doi-asserted-by":"crossref","unstructured":"Bai F, Watson DR, Shi Y, et al. Specifically progressive deficits of brain functional marker in amnestic type mild cognitive impairment. PLoS One. 2011;6(9).","DOI":"10.1371\/journal.pone.0024271"},{"issue":"5","key":"3805_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as Prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648\u201358.","journal-title":"Ann Neurol"},{"key":"3805_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","volume":"11","author":"V Chouraki","year":"2015","unstructured":"Chouraki V, Beiser A, Younkin L, et al. Plasma amyloid\u2013beta and risk of Alzheimer\u2019s disease in the Framingham heart study. Alzheimers Dement. 2015;11:249\u201357.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"3805_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.2010.1995","volume":"305","author":"K Yaffe","year":"2011","unstructured":"Yaffe K, Weston A, Graff-Radford NR, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305(3):261\u20136.","journal-title":"JAMA."}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03805-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-022-03805-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03805-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:29:20Z","timestamp":1669976960000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-022-03805-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3805"],"URL":"https:\/\/doi.org\/10.1186\/s12906-022-03805-9","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial will be performed in accordance with the Declaration of Helsinki and Korean Good Clinical Practice Guidelines. The protocol of this trial was approved by the Institutional Review Board of Kyung Hee University Hospital at Gangdong (KHNMC-OH-IRB 2021\u201312-004) and the Korean Ministry of Food and Drug Safety (32756) and is registered at the Korean Clinical Trial Registry (). The current protocol version (3.1) was approved on March 29th, 2022 and developed according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement (see Additional\u00a0file\u00a0). All items were drawn from the World Health Organization Trial Registration Dataset. All modifications to the protocol will be approved by the institutional review board before implementation. Signed informed consent will be obtained from all qualified participants by a clinical research coordinator and\/or study investigators. Participation in this study is voluntary, and participants can withdraw from the study at any given point.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}